<SEC-DOCUMENT>0001193125-23-262213.txt : 20231025
<SEC-HEADER>0001193125-23-262213.hdr.sgml : 20231025
<ACCEPTANCE-DATETIME>20231025060725
ACCESSION NUMBER:		0001193125-23-262213
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231025
FILED AS OF DATE:		20231025
DATE AS OF CHANGE:		20231025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231343837

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d533951d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October 25, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d533951dex991.htm">Immutep receives ~A$1.13 million R&amp;D Tax Incentive </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 25, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d533951dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g533951dsp04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25&nbsp;October 2023 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep receives
~A$1.13&nbsp;million R&amp;D Tax Incentive </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or the
&#147;Company&#148;), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government&#146;s R&amp;D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&amp;D
activities conducted in the 2022 fiscal year, mainly related to the Company&#146;s <FONT STYLE="white-space:nowrap">TACTI-002</FONT> and <FONT STYLE="white-space:nowrap">TACTI-003</FONT> clinical study using its lead compound eftilagimod alpha
(&#147;efti&#148; or &#147;IMP321&#148;), conducted in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This follows approval from AusIndustry of Immutep&#146;s application for an
Advance/Overseas Finding. Due to the Advance Finding, both Immutep&#146;s Australian and overseas research and development activities related to the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> and
<FONT STYLE="white-space:nowrap">TACTI-003</FONT> Australian sites were eligible for the R&amp;D Tax Incentive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep also receives the French CIR tax
incentive through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&amp;D activities conducted in the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep
will apply the <FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into early calendar year
2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage
biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g533951dsp04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g533951dsp04.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M+1LNC$?N8(_O'W[T =]X*\/R:)IKO=*!=W!!8?W0.@_G0!U% !0 4 (: #%
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M[UOE)('W&H J7,DXL=9,K*KJO&UC@?(.] #BT*:3J!MWMMXA8_Z.^<?*?RH
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+ !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
